Rhonda Farnum
Vermogen: 4 M $ op 31-05-2026
Vermogen: 4 M $ op 31-05-2026
Rhonda F.
Farnum is currently Chief Business Officer & SVP-Medical Affairs at Theravance Biopharma, Inc., a position held since 2021, with employment at the firm starting in 2018.
Formerly, Ms. Farnum was Head of the Hematology Business Unit at Onyx Pharmaceuticals, Inc. from 2014 to 2015.
Education includes undergraduate studies at the University of Georgia.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 15-06-2026 | 232.457 ( 0,45% ) | 4 M $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| THERAVANCE BIOPHARMA, INC. | Hoofd Techniek/Wetenschap/O&O | - |
| Bedrijven | Functie | Einde |
|---|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Corporate Officer/Principal | 01-08-2015 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 3 |
|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Health Technology |
University of Georgia
University of Georgia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Theravance Biopharma, Inc.
Theravance Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Engages in the discovery, development and commercialization of human therapeutics products for respiratory diseases | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau